Frontiers in endocrinology · 2026
Adipokine profiles and genetic variants of leptin receptor, adiponectin, and ghrelin pathways in obesity: prospective 12-month outcomes after bariatric interventions.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Prodan Andriy, Dzyubanovsky Ihor, Halabitska Iryna, Petakh Pavlo, Kamyshna Iryna, Kamyshnyi Oleksandr
Аннотация
INTRODUCTION: Adipokines and genetic factors play an important role in the development of obesity and its metabolic complications. The study aimed to assess the relationships among genetic polymorphisms, adipokine levels, and clinical and metabolic indicators in patients with varying degrees of obesity, and to analyze changes in anthropometric and metabolic parameters after bariatric interventions.
METHODS: A prospective observational study included 76 adult patients with obesity, divided by body mass index. Anthropometric indicators, glycated hemoglobin levels, and adipokine concentrations (leptin, adiponectin, resistin, and total ghrelin) were determined. Genotyping of polymorphisms (rs1137101, rs1137100, rs7799039, rs266729, rs17300539, rs1805094, rs696217) was performed using standard molecular genetic methods. Patients underwent bariatric surgery (endovascular embolization, gastroplication, or sleeve gastrectomy) with a 12-month follow-up.
RESULTS: With increasing obesity, resistin and leptin levels increase, while adiponectin and ghrelin levels decrease (p < 0.05). The rs1137101 and rs696217 polymorphisms are associated with the degree of obesity: the A allele of rs1137101 is less common in patients with stage III. At the same time, the GG genotype is more prevalent in critically ill patients (p < 0.01). Bariatric interventions effectively reduce BMI and body weight, improve glycemic control, and normalize the hormonal profile (p < 0.001). The T allele of rs696217 and G of rs1137101 affect weight dynamics and hormonal changes after surgery.
CONCLUSIONS: The hormonal profile and genetic variants of rs1137101 and rs696217 affect the severity of obesity and the effectiveness of bariatric treatment. Genetic testing may help predict outcomes and personalize therapy.
METHODS: A prospective observational study included 76 adult patients with obesity, divided by body mass index. Anthropometric indicators, glycated hemoglobin levels, and adipokine concentrations (leptin, adiponectin, resistin, and total ghrelin) were determined. Genotyping of polymorphisms (rs1137101, rs1137100, rs7799039, rs266729, rs17300539, rs1805094, rs696217) was performed using standard molecular genetic methods. Patients underwent bariatric surgery (endovascular embolization, gastroplication, or sleeve gastrectomy) with a 12-month follow-up.
RESULTS: With increasing obesity, resistin and leptin levels increase, while adiponectin and ghrelin levels decrease (p < 0.05). The rs1137101 and rs696217 polymorphisms are associated with the degree of obesity: the A allele of rs1137101 is less common in patients with stage III. At the same time, the GG genotype is more prevalent in critically ill patients (p < 0.01). Bariatric interventions effectively reduce BMI and body weight, improve glycemic control, and normalize the hormonal profile (p < 0.001). The T allele of rs696217 and G of rs1137101 affect weight dynamics and hormonal changes after surgery.
CONCLUSIONS: The hormonal profile and genetic variants of rs1137101 and rs696217 affect the severity of obesity and the effectiveness of bariatric treatment. Genetic testing may help predict outcomes and personalize therapy.